Article Details
Retrieved on: 2023-01-09 19:48:22
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The companies noted that neutropenia events were manageable with dose reductions for palbociclib. Due to the recent data analysis, the companies plan ...
Article found on: seekingalpha.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here